Comparative Pharmacology
Head-to-head clinical analysis: CABERGOLINE versus DOSTINEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CABERGOLINE versus DOSTINEX.
CABERGOLINE vs DOSTINEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by the anterior pituitary gland.
Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by binding to D2 receptors on lactotroph cells in the anterior pituitary.
0.25 mg orally twice weekly, up to 1 mg twice weekly; for hyperprolactinemia, initial 0.25 mg twice weekly, titrate by 0.25 mg every 4 weeks based on prolactin levels.
0.25 mg orally twice weekly, with a minimum of 2 days between doses; may increase by 0.25 mg twice weekly every 4 weeks up to a maximum of 1 mg twice weekly.
None Documented
None Documented
Terminal elimination half-life is 63-68 hours in healthy subjects, allowing for once- or twice-weekly dosing. In hepatic impairment, half-life may be prolonged.
Clinical Note
moderateCabergoline + Digoxin
"Cabergoline may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCabergoline + Digitoxin
"Cabergoline may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCabergoline + Deslanoside
"Cabergoline may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCabergoline + Acetyldigitoxin
"Cabergoline may decrease the cardiotoxic activities of Acetyldigitoxin."
The terminal elimination half-life is 63–69 hours in healthy volunteers and 79–115 hours in patients with hyperprolactinemia, allowing once- or twice-weekly dosing. The long half-life reflects slow dissociation from D2 receptors and enterohepatic recirculation.
Approximately 60-70% of the dose is excreted in feces (primarily as unchanged drug and metabolites), with about 20-30% excreted renally (mostly as metabolites).
Cabergoline is extensively metabolized in the liver, primarily via CYP3A4. Elimination is predominantly fecal (60%) and renal (20%) as metabolites, with <4% as unchanged drug. Biliary excretion contributes to fecal elimination.
Category A/B
Category C
Dopamine Agonist
Dopamine Agonist